New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence